NPC Archive Item: Key licensing studies for indacaterol in COPD published

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 31 August 2010 Indacaterol▼ inhaled once daily improved trough FEV1 at 12 weeks compared to placebo in patients with moderate to severe COPD. Results from the 52-week INVOLVE study […]

NPC Archive Item: Pre-planned analysis of PLATO study of aspirin plus ticagrelor or clopidogrel in patients undergoing early invasive intervention for ACS

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 18 August 2010 Early invasive intervention for acute coronary syndrome was planned for 13,408 patients in this pre-specified analysis of the PLATO study (total n=18,624). After 12 months, ticagrelor plus […]

NPC Archive Item: Lasofoxifene for postmenopausal osteoporosis

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 15 April 2010 In the PEARL study of 8,556 women with postmenopausal osteoporosis, lasofoxifene 0.5mg daily reduced the risk of radiographic vertebral fractures after three years. At the end of […]

NPC Archive Item: Disappointing results for cangrelor in patients undergoing PCI

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 29 March 2010 Intravenous cangrelor has failed to show a benefit on the primary end point of a composite of death, myocardial infarction (MI) or ischaemia-driven revascularisation 48 hours […]

NPC Archive Item: Cladribine – another potential new oral treatment for MS?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 23 March 2010 Oral cladribine, given as one of two cumulative doses (either 3.5mg or 5.25mg/kg) in short courses, was more effective at preventing relapse than placebo in the […]

NPC Archive Item: Liraglutide▼ for the treatment of obesity

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 04 March 2010 Obese, non-diabetic patients received one of four doses of liraglutide▼ subcutaneously once a day versus open-label orlistat orally three times a day in a European, phase […]